|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Louisiana State University Centers for Disease Control and Prevention |
|---|---|
| Information provided by: | Louisiana State University |
| ClinicalTrials.gov Identifier: | NCT00380679 |
Purpose
According to the Advisory Committee on Immunization Practices (ACIP), all people aged 50 years or older and persons aged less than 50 years who have medical conditions that put them at increased risk for serious influenza disease should receive an annual influenza vaccination. However, since the mid-1990s, vaccination rates and racial disparities have mostly remained static, and there has been limited progress towards the Healthy People 2010 objectives for influenza vaccination coverage.
The purpose of this study is to determine what proportion of previously unvaccinated persons in target groups for whom influenza and pneumococcal vaccine are recommended will accept and receive influenza and/or pneumococcal vaccine in an urban emergency department (ED), and to estimate the potential impact of ED vaccination on population-based vaccination coverage. The intervention will utilize a combination of assessment survey, vaccine information and pre-printed vaccine order sheets.
The target population for influenza vaccinations includes all patients aged 18 years and older for whom influenza vaccine is recommended by the ACIP.
This includes all persons aged 50 years and older and persons aged 18 to 49 years who are in one of the following groups: 1) health care workers, 2) pregnant women, 3) residents of long-term care facilities, 4) household contacts and out-of-home caregivers of children aged 0 to 23 months, or 5) persons with underlying chronic medical conditions which increase their risk of influenza-related complications. The target population for pneumococcal vaccination includes all patients aged 65 years or older who have not previously been vaccinated against pneumococcus or have not received the vaccine within 5 years (and were less than 65 years at the time of vaccination).
| Condition | Intervention | Phase |
|---|---|---|
|
High Risk for Serious Influenza High Risk for Pneumonia |
Biological: Influenza vaccination Biological: Pneumococcal polysaccharide vaccination |
Phase II |
| Study Type: | Interventional |
| Study Design: | Prevention, Non-Randomized, Open Label, Historical Control, Single Group Assignment |
| Official Title: | Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department |
| Study Start Date: | December 2005 |
| Estimated Study Completion Date: | March 2006 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Baton Rouge General Medical Center
Inclusion Criteria:
Exclusion Criteria:
Our Lady of the Lake Regional Medical Center
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Louisiana | |
| Baton Rouge General Medical Center | |
| Baton Rouge, Louisiana, United States, 70806 | |
| Our Lady of the Lake Regional Medical Center | |
| Baton Rouge, Louisiana, United States, 70808 | |
| Principal Investigator: | William M Cassidy, MD | Louisiana State University Health Sciences Center |
| Principal Investigator: | Daniel Fishbein, MD | Centers for Disease Control and Prevention |
More Information
| Study ID Numbers: | 5800 |
| Study First Received: | September 25, 2006 |
| Last Updated: | September 25, 2006 |
| ClinicalTrials.gov Identifier: | NCT00380679 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Virus Diseases Respiratory Tract Diseases Respiratory Tract Infections Lung Diseases |
Influenza, Human Emergencies Orthomyxoviridae Infections Pneumonia |
|
Virus Diseases RNA Virus Infections Disease Attributes Pathologic Processes Respiratory Tract Diseases Respiratory Tract Infections |
Lung Diseases Influenza, Human Emergencies Orthomyxoviridae Infections Pneumonia |